Alzheimer's disease and Parkinson's disease

New England Journal of Medicine

Volumn 348, Issue 14, 2003, Pages 1356-1364

  Nussbaum, Robert L ^a   Ellis, Christopher E ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; PARKIN; PRESENILIN 1; TAU PROTEIN;

AGED; ALLELE; ALZHEIMER DISEASE; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; DISEASE PREDISPOSITION; FAMILIAL DISEASE; FEMALE; GENE ISOLATION; GENE MAPPING; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; MALE; MISSENSE MUTATION; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN PRECURSOR; APOLIPOPROTEINS E; HUMANS; LEWY BODIES; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; NERVE TISSUE PROTEINS; PARKINSONIAN DISORDERS; PREVALENCE; SUBSTANTIA NIGRA; SYNUCLEINS;

EID: 0037417254     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM2003ra020003     Document Type: Review

References (82)

1. Garrod A. The lessons of rare maladies. Lancet 1928;1:1055-60.
2. Martin JB. Molecular basis of the neurodegenerative disorders. N Engl J Med 1999; 340:1970-80. [Erratum, N Engl J Med 1999; 341:1407.]
3. Helmer C, Joly P, Letenneur L, Commenges D, Dartigues JF. Mortality with dementia: results from a French prospective community-based cohort. Am J Epidemiol 2001;154:642-8.
4. Aronson MK, Ooi WL, Geva DL, Masur D, Blau A, Frishman W. Dementia: age-dependent incidence, prevalence, and mortality in the old old. Arch Intern Med 1991; 151:989-92.
5. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
6. Clark CM, Ewbank D, Lee VM-Y, Trojanowski JQ. Molecular pathology of Alzheimer's disease: neuronal cytoskeletal abnormalities. In: Growdon JH, Rossor MN, eds. The dementias. Vol. 19 of Blue books of practical neurology. Boston: Butterworth-Heinemann, 1998:285-304.
7. Hutton M, Perez-Tur J, Hardy J. Genetics of Alzheimer's disease. Essays Biochem 1998;33:117-31.
8. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994;13:45-53.
9. Esler WP, Wolfe MS. A portrait of Alzheimer secretases - new features and familiar faces. Science 2001;293:1449-54.
10. Hy LX, Keller DM. Prevalence of AD among whites: a summary by levels of severity. Neurology 2000;55:198-204.
11. Hendrie HC, Ogunniyi A, Hall KS, et al. Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA 2001;285:739-47.
12. Campion D, Dumanchin C, Hannequin D, et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 1999;65:664-70.
13. Steiner H, Haass C. Intramembrane proteolysis by presenilins. Nat Rev Mol Cell Biol 2000;1:217-24.
14. Borchelt DR, Thinakaran G, Eckman CB, et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta 1-42/1-40 ratio in vitro and in vivo. Neuron 1996;17: 1005-13.
15. Wolfe MS, Xia W, Ostaszewsld BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gammasecretase activity. Nature 1999;398:513-7.
16. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to thatin the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996;2: 864-70.
17. Murayama O, Tomita T, Nihonmatsu N, et al. Enhancement ofamyloid beta 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer's disease. Neurosci Lett 1999;265:61-3.
18. Mehta ND, Refolo LM, Eckman C, et al. Increased Abeta42(43) from cell lines expressing presenilin 1 mutations. Ann Neurol 1999; 43:256-8.
19. Eckman CB, Mehta ND, Crook R, et al. A new pathogenic mutation in the APP gene (1716V) increases the relative proportion of A beta 42(43). Hum Mol Genet 1997;6: 2087-9.
20. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-6. [Erratum, Science 2002; 297:2209.]
21. Lynch T, Sano M, Marder KS, et al. Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology 1994;44:1878-84.
22. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393:702-5.
23. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer's disease. Annu Rev Neurosci 1996;19:53-77.
24. Seshadri S, Drachman DA, Lippa CF. Apolipoprotein E epsilon 4 allele and the lifetime risk of Alzheimer's disease: what physicians know, and what they should know. Arch Neurol 1995;52:1074-9.
25. Meyer MR, Tschanz JT, Norton MC, et al. APOE genotype predicts when - not whether - one is predisposed to develop Alzheimer disease. Nat Genet 1998;19:321-2.
26. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA 1997;278:1349-56.
27. Myers AJ, Goate AM. The genetics of late-onset Alzheimer's disease. Curr Opin Neurol 2001;14:433-40.
28. Saunders AM, Hulette O, Welsh-Bohmer KA, et al. Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. Lancet 1996;348:90-3.
29. Chapman PF, Falinska AM, Knevett SG, Ramsay MF. Genes, models and Alzheimer's disease. Trends Genet 2001;17:254-61.
30. Citron M. Beta-secretase as a target for the treatment of Alzheimer's disease. J Neurosci Res 2002;70:373-9.
31. Moechars D, Lorent K, De Strooper B, Dewachter I, Van Leuven F. Expression in brain of amyloid precursor protein mutated in the α-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. EMBO J 1996;15: 1265-74.
32. Holcomb L, Gordon MN, McGowan E, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998;4:97-100.
33. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-7.
34. Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000;408:982-5. [Erratum, Nature 2001;412:660.]
35. Helmuth L. Alzheimer's congress: further progress on a beta-amyloid vaccine. Science 2000;289:375.
36. Check E. Nerve inflammation halts trial for Alzheimer's drug. Nature 2002;415:462.
37. Birmingham K, Frantz S. Setback to Alzheimer vaccine studies. Nat Med 2002;8: 199-200.
38. De Strooper B, Konig G. An inflammatory drug prospect. Nature 2001;414:159-60.
39. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
40. Pollanen MS, Dickson DW, Bergeron C. Pathology and biology of the Lewy body. J Neuropathol Exp Neurol 1993;52:183-91.
41. Kuzuhara S, Mori H, Izumiyama N, Yoshimura M, Ihara Y. Lewy bodies are ubiquitinated: a light and electron microscopic immunocytochemical study. Acta Neuropathol (Berl) 1988;75:345-53.
42. Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. Neurol Clin 1996;14: 317-35.
43. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
44. Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study. JAMA 1999;281:341-6.
45. Duvoisin RC, Johnson WG. Hereditary Lewy-body parkinsonism and evidence for a genetic etiology of Parkinson's disease. Brain Pathol 1992;2:309-20.
46. Burn DJ, Mark MH, Playford ED, et al. Parkinson's disease in twins studied with 18F-dopa and positron emission tumography. Neurology 1992;42:1894-900.
47. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998; 64:314-9.
48. Marder K, Tang M-X, Mejia H, et al. Risk of Parkinson's disease among first-degree relatives: a community-based study. Neurology 1996;47:155-60.
49. Payami H, Larsen K, Bernard S, Nutt J. Increased risk of Parkinson's disease in parents and siblings of patients. Ann Neurol 1994;36:659-61.
50. Piccini P, Morrish PK, Turjanski N, et al. Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa positron emission tomography study. Ann Neurol 1997;41:222-9.
51. Duvoisin RC. Recent advances in the genetics of Parkinson's disease. Adv Neurol 1996;69:33-40.
52. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-7.
53. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998;18:106-8.
54. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. α-Synuclein in Lewy bodies. Nature 1997;388: 839-40.
55. Mezey E, Dehejia AM, Harta G, et al. Alpha synuclein is present in Lewy bodies in sporadic Parkinson's disease. Mol Psychiatry 1998;3:493-9. [Erratum, Mol Psychiatry 1999;4:197.]
56. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A 2000;97: 571-6.
57. Louis ED, Fahn S. Pathologically diagnosed diffuse Lewy body disease and Parkinson's disease: do the parkinsonian features differ? Adv Neurol 1996;69:311-4.
58. Kosaka K, Iseki E. Dementia with Lewy bodies. Curr Opin Neurol 1996;9:271-5.
59. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 1998;251:205-8.
60. Galvin JE, Lee VM, Trojanowski JQ. Synucleinopathies: clinical and pathological implications. Arch Neurol 2001;58:186-90.
61. Matsumine H, Saito M, Shimoda-Matsubayashi S, et al. Localization of a gene for an autosomal recessive form of juvenile parkinsonism to chromosome 6q25.2-27. Am J Hum Genet 1997;60:588-96.
62. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-8.
63. Abbas N, Lucking CB, Ricard S, et al. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. Hum Mol Genet 1999;8:567-74.
64. Lucking CB, Abbas N, Durr A, et al. Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism. Lancet 1998;352:1355-6.
65. Lücking CB, Dürr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000;342:1560-7.
66. Farrer M, Chan P, Chen R, et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 2001;50: 293-300.
67. Shimura H, Schlossmacher MG, Hattori N, et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 2001;293:263-9.
68. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease. Nature 1998;395:451-2.
69. Farrer M, Gwinn-Hardy K, Muenter M, et al. A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor. Hum Mol Genet 1999;8:81-5.
70. Gasser T, Muller-Myhsok B, Wszolek ZK, et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet 1998;18:262-5.
71. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 2002;51: 296-301.
72. Valente EM, Bentivoglio AR, Dixon PH, et al. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am J Hum Genet 2001;68:895-900.
73. van Duijn CM, Dekker MC, Bonifati V, et al. Park7, a novel locus for autosomal recessive early-onset parldnsonism, on chromosome 1p36. Am J Hum Genet 2001;69:629-34.
74. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003;299:256-9.
75. Scott WK, Nance MA, Watts RL, et al. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA 2001;286:2239-44.
76. Pankratz N, Nichols WC, Uniacke SK, et al. Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am J Hum Genet 2002;71:124-35.
77. Hicks AA, Petursson H, Jonsson T, et al. A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann Neurol 2001;52:549-55.
78. Sveinbjörnsdóttir S, Hicks AA, Jónsson T, et al. Familial aggregation of Parkinson's disease in Iceland. N Engl J Med 2000;343: 1765-70.
79. Tan EK, Matsuura T, Nagamitsu S, Khajavi M, Jankovic J, Ashizawa T. Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor? Neurology 2000;54:1195-8.
80. Kruger R, Vieira-Saecker AM, Kuhn W, et al. Increased susceptibility to sporadic Parkinson's disease by a certain combined alphasynuclein/apolipoprotein E genotype. Ann Neurol 1999;45:611-7.
81. Farrer M, Maraganore DM, Lockhart P, et al. Alpha-synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet 2001;10:1847-51.
82. Izumi Y, Morino H, Oda M, et al. Genetic studies in Parkinson's disease with an alphasynuclein/NACP gene polymorphism in Japan. Neurosci Lett 2001;300:125-7.